SILO Silo Pharma Inc.

Subscribe to $SILO

Silo Pharma Inc.

Subscribe to $SILO

$SILO

Apparel

Consumer Discretionary

IPO Year:

Exchange: NASDAQ

Recent Analyst Ratings for Silo Pharma Inc.

Date	Price Target	Rating	Analyst

See more ratings

Silo Pharma Inc. Press Releases

Fastest customizable press release news feed in the world

Silo Pharma Announces Closing of $2 Million Public Offering
SARASOTA, FL, May 16, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or the "Company"), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, closed on the previously announced public offering of 3,333,338 shares of common stock (or pre-funded warrants in lieu thereof), together with series A-1 warrants ("Series A-1 Warrants") to purchase up to 3,333,338 shares of common stock and series A-2 warrants ("Series A-2 Warrants") to purchase up to 3,333,338 shares of common stock at a combined public offering price of $0.60 per share (or pre-funded warrant in lieu thereof) and associated Series A-1 Warrant and Series A-2 Warran
5/16/25 4:15:00 PM ET
$SILO
Apparel
Consumer Discretionary
Silo Pharma Announces Pricing of $2 Million Public Offering
SARASOTA, FL, May 15, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or the "Company"), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced the pricing of a public offering of 3,333,338 shares of common stock (or pre-funded warrants in lieu thereof), together with series A-1 warrants ("Series A-1 Warrants") to purchase up to 3,333,338 shares of common stock and series A-2 warrants ("Series A-2 Warrants") to purchase up to 3,333,338 shares of common stock at a combined public offering price of $0.60 per share (or pre-funded warrant in lieu thereof) and associated Series A-1 Warrant and Series A-2 Warrant.
5/15/25 9:15:00 AM ET
$SILO
Apparel
Consumer Discretionary
Silo Pharma Selects Veloxity Labs for Bioanalytical IND-Enabling Study for our Novel Intranasal PTSD Therapy, SPC-15
SARASOTA, FL, May 14, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or the "Company"), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced that it has engaged Veloxity Labs, LLC for bioanalysis supporting the ongoing investigational new drug (IND)-enabling GLP (Good Laboratory Practice)-compliant toxicology and toxicokinetics study of its lead asset, SPC-15, an intranasal prophylactic treatment for post-traumatic stress disorder (PTSD). "We look forward to working with Veloxity Labs for GLP sample analysis in our current safety study of SPC-15," said Eric Weisblum, CEO of Silo. "We expect Veloxity to p
5/14/25 4:07:00 PM ET
$SILO
Apparel
Consumer Discretionary
Silo Pharma Advances PTSD Drug SPC-15 Toward First-in-Human Trial with Key Safety Study Initiated at Frontage Laboratories
SARASOTA, FL, May 14, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or the "Company"), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced that it has entered into an agreement with Frontage Laboratories, a global full-service CRO (contract research organization), for a Food and Drug Administration (FDA) requested 7-day safety and toxicology large animal study of its lead asset SPC-15, an intranasal prophylactic treatment for post-traumatic stress disorder (PTSD). "We are conducting a 7-day safety and toxicology study to gather additional data that is expected to supplement and reinforce our SPC-15 inv
5/14/25 8:40:00 AM ET
$SILO
Apparel
Consumer Discretionary
Silo Pharma's SP-26 Ketamine Implant Meets All Endpoints in Fibromyalgia Study
— Successfully demonstrates strong tolerability, sustained drug release and safety SARASOTA, FL, April 30, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo," or the "Company"), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced positive results for its preclinical study evaluating SP-26, a novel extended-release ketamine implant which it believes supports SP-26's potential as a safe, well-tolerated, and long-acting treatment for fibromyalgia. All study endpoints were met, including survival, clinical observations, body weight stability, neurological assessments, and histopathological evaluation. "Our t
4/30/25 8:11:00 AM ET
$SILO
Apparel
Consumer Discretionary
Silo Pharma Expands Intellectual Property Portfolio with Patent Application for Exclusively Licensed Alzheimer's Drug
SARASOTA, FL, April 28, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or the "Company"), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced the filing of a patent application with the U.S. Patent and Trademark Office (USPTO) focused on the neurology drug SPC-14, an intranasal compound for the treatment of Alzheimer's disease (AD) exclusively licensed to Silo Pharma from Columbia University. The patent, titled "Compositions and Methods for the Treatment of Alzheimer's Disease and Other Neurogenerative Disease," covers SPC-14's novel mechanism of action for targeting glutamate receptor NDMAR and seroto
4/28/25 7:50:00 AM ET
$SILO
Apparel
Consumer Discretionary
Silo Pharma Achieves Key Milestone with First Dosing in IND-Enabling GLP Study for SPC-15 as a Groundbreaking PTSD Treatment
Preclinical Data to Support Advancement Toward First-in-Human Clinical Trials SARASOTA, FL, March 26, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or the "Company"), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced first dosing in an investigational new drug (IND)-enabling GLP (Good Laboratory Practice)-compliant toxicology and toxicokinetics study of its lead asset, SPC-15, an intranasal prophylactic treatment for post-traumatic stress disorder (PTSD). "This IND-enabling safety study and our concurrent GLP-compliant pharmacokinetic and pharmacodynamic study, if successful, will provide the last
3/26/25 8:40:00 AM ET
$SILO
Apparel
Consumer Discretionary
Silo Pharma Granted U.S. Patent for Novel Intranasal Post-Traumatic Stress Disorder Treatment
SARASOTA, FL, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or the "Company"), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced that the U.S. Patent and Trademark Office (USPTO) issued an Issue Notification for our previously filed patent application (No. 17/954,864) titled "Pharmacological Prophylactics Against Stress-Induced Affective Disorders in Females." The projected patent number is 12,239,614 and the issue date of such patent will be March 4, 2025. The patent reinforces protection for Silo's lead asset, SPC-15, an intranasal treatment targeting post-traumatic stress disorder (PTSD
2/26/25 1:30:00 PM ET
$SILO
Apparel
Consumer Discretionary
Silo Pharma Expands Intellectual Property Portfolio with Provisional Patent Filing for Innovative SPC-15 Combination Treatment
SPC-15 combination treatment shows enhanced efficacy in combating stress-induced psychiatric disorders SARASOTA, FL, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or the "Company"), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced the filing of a provisional patent application with the U.S. Patent and Trademark Office (USPTO) for its lead asset SPC-15. Silo currently has patents issued and numerous expanded patent applications pending for SPC-15, a technology that was originally licensed through a collaboration with Columbia University. The provisional patent covers a dual-action method
2/18/25 8:50:00 AM ET
$SILO
Apparel
Consumer Discretionary
Silo Pharma Announces Positive Initial Pharmacokinetic, Safety, and Tolerability Study of SP-26 for Chronic Pain and Fibromyalgia
No serious side effects or discomfort observed Final safety and absorption data expected in March 2025 SARASOTA, FL, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or the "Company"), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced a positive update from an ongoing study evaluating the pharmacokinetics, safety and tolerability of its novel SP-26 ketamine extended-release rods when implanted subcutaneously. The SP-26 implant is a novel self-administered, non-opioid therapeutic intended for the treatment of chronic pain and fibromyalgia. The launch of our non-GLP study in December 2024 mar
2/11/25 7:45:00 AM ET
$SILO
Apparel
Consumer Discretionary

Silo Pharma Inc.

Recent Analyst Ratings for Silo Pharma Inc.

Silo Pharma Inc.

Recent Analyst Ratings for Silo Pharma Inc.

Silo Pharma Inc. SEC Filings

Silo Pharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

SEC Form 424B4 filed by Silo Pharma Inc.

SEC Form EFFECT filed by Silo Pharma Inc.

Amendment: SEC Form S-1/A filed by Silo Pharma Inc.

SEC Form 10-Q filed by Silo Pharma Inc.

Amendment: SEC Form S-1/A filed by Silo Pharma Inc.

SEC Form S-1 filed by Silo Pharma Inc.

SEC Form 424B3 filed by Silo Pharma Inc.

SEC Form EFFECT filed by Silo Pharma Inc.

SEC Form POS AM filed by Silo Pharma Inc.

Silo Pharma Inc. Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G filed by Silo Pharma Inc.

SEC Form SC 13G filed by Silo Pharma Inc.

SEC Form SC 13G/A filed by Silo Pharma Inc. (Amendment)

SEC Form SC 13G/A filed by Silo Pharma Inc. (Amendment)

Silo Pharma Inc. Press Releases

Fastest customizable press release news feed in the world

Silo Pharma Announces Closing of $2 Million Public Offering

Silo Pharma Announces Pricing of $2 Million Public Offering

Silo Pharma Selects Veloxity Labs for Bioanalytical IND-Enabling Study for our Novel Intranasal PTSD Therapy, SPC-15

Silo Pharma Advances PTSD Drug SPC-15 Toward First-in-Human Trial with Key Safety Study Initiated at Frontage Laboratories

Silo Pharma's SP-26 Ketamine Implant Meets All Endpoints in Fibromyalgia Study

Silo Pharma Expands Intellectual Property Portfolio with Patent Application for Exclusively Licensed Alzheimer's Drug

Silo Pharma Achieves Key Milestone with First Dosing in IND-Enabling GLP Study for SPC-15 as a Groundbreaking PTSD Treatment

Silo Pharma Granted U.S. Patent for Novel Intranasal Post-Traumatic Stress Disorder Treatment

Silo Pharma Expands Intellectual Property Portfolio with Provisional Patent Filing for Innovative SPC-15 Combination Treatment

Silo Pharma Announces Positive Initial Pharmacokinetic, Safety, and Tolerability Study of SP-26 for Chronic Pain and Fibromyalgia

Silo Pharma Inc. Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

CEO and President Weisblum Eric bought $2,097 worth of shares (2,500 units at $0.84), increasing direct ownership by 1% to 187,932 units (SEC Form 4)

CEO and President Weisblum Eric bought $4,625 worth of shares (5,000 units at $0.93), increasing direct ownership by 3% to 185,432 units (SEC Form 4)

CEO and President Weisblum Eric bought $5,533 worth of shares (5,000 units at $1.11), increasing direct ownership by 3% to 180,432 units (SEC Form 4)

Weisblum Eric bought $1,988 worth of shares (1,000 units at $1.99), increasing direct ownership by 0.57% to 175,432 units (SEC Form 4)

Weisblum Eric bought $8,713 worth of shares (4,508 units at $1.93), increasing direct ownership by 3% to 174,432 units (SEC Form 4)

Weisblum Eric bought $1,137 worth of shares (700 units at $1.62), increasing direct ownership by 0.41% to 169,924 units (SEC Form 4)

Weisblum Eric bought $1,668 worth of shares (1,100 units at $1.52), increasing direct ownership by 0.65% to 169,224 units (SEC Form 4)

Weisblum Eric bought $1,376 worth of shares (1,000 units at $1.38), increasing direct ownership by 0.60% to 168,124 units (SEC Form 4)

Weisblum Eric bought $3,100 worth of shares (2,000 units at $1.55), increasing direct ownership by 1% to 167,124 units (SEC Form 4)

Weisblum Eric bought $1,117 worth of shares (650 units at $1.72), increasing direct ownership by 0.40% to 165,124 units (SEC Form 4)

Silo Pharma Inc. Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

CEO and President Weisblum Eric bought $2,097 worth of shares (2,500 units at $0.84), increasing direct ownership by 1% to 187,932 units (SEC Form 4)

CEO and President Weisblum Eric bought $4,625 worth of shares (5,000 units at $0.93), increasing direct ownership by 3% to 185,432 units (SEC Form 4)

CEO and President Weisblum Eric bought $5,533 worth of shares (5,000 units at $1.11), increasing direct ownership by 3% to 180,432 units (SEC Form 4)

Weisblum Eric bought $1,988 worth of shares (1,000 units at $1.99), increasing direct ownership by 0.57% to 175,432 units (SEC Form 4)

Weisblum Eric bought $8,713 worth of shares (4,508 units at $1.93), increasing direct ownership by 3% to 174,432 units (SEC Form 4)

Weisblum Eric bought $1,137 worth of shares (700 units at $1.62), increasing direct ownership by 0.41% to 169,924 units (SEC Form 4)

Weisblum Eric bought $1,668 worth of shares (1,100 units at $1.52), increasing direct ownership by 0.65% to 169,224 units (SEC Form 4)

Weisblum Eric bought $1,376 worth of shares (1,000 units at $1.38), increasing direct ownership by 0.60% to 168,124 units (SEC Form 4)

Weisblum Eric bought $3,100 worth of shares (2,000 units at $1.55), increasing direct ownership by 1% to 167,124 units (SEC Form 4)

Weisblum Eric bought $1,117 worth of shares (650 units at $1.72), increasing direct ownership by 0.40% to 165,124 units (SEC Form 4)